Product Details

Zofran

Ondansetron Hydrochloride
8 mg
Tablet


DIN/PIN/NPN

02213575

Manufacturer

Novartis Pharma Canada Inc.

Formulary Listing Date

1997-01-20  

Unit Price

23.6170

Amount MOH Pays

3.8840

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AA01

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02213575 Zofran 23.6170 3.8840
02376105 Septa-Ondansetron 5.1110 3.8840
02274329 Sandoz Ondansetron 5.1110 3.8840
02312255 Ran-Ondansetron 5.1110 3.8840
02258196 PMS-Ondansetron 5.1110 3.8840
02421410 Ondansetron 4.9930 3.8840
02417847 Nat-Ondansetron 5.1110 3.8840
02297876 Mylan-Ondansetron 5.1110 3.8840
02305267 Mint-Ondansetron 5.1110 3.8840
02371758 Mar-Ondansetron 5.1110 3.8840
02313693 Jamp-Ondansetron 5.1110 3.8840
02458802 CCP-Ondansetron 5.1110 3.8840
02288192 Apo-Ondansetron 5.1110 3.8840
02296357 Teva-Ondansetron 5.1110 3.8840
02478935 Accel-Ondansetron 3.8840 3.8840
02541432 Ondansetron 5.1110 3.8840
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
Note: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven
215 1 year

For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy

216 1 year

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics

217 1 year

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics

218 1 year

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.

454 1 year

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens

 

EAP Criteria

Therapeutic Class Reimbursement Criteria
Unclassified EAP Drugs

These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition

Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding.

Product Monograph

View Monograph